MedTrace Logo

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

NCT06693336 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-03-06

No results posted yet for this study

Summary

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.

Conditions

  • Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

Interventions

DRUG

SMS001

One time administration

Sponsors & Collaborators

  • Toronto General Hospital / University Health Network (UHN)

    collaborator UNKNOWN

  • Mayo Clinic, Rochester, MN

    collaborator UNKNOWN

  • ToLymph Inc.

    lead INDUSTRY

Principal Investigators

  • Kazuhiro Yasufuku MD, PhD, FRCSC · Toronto General Hospital / University Health Network (UHN)

  • Janani S Reisenauer, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2026-11-18
Completion
2026-12-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06693336 on ClinicalTrials.gov